Huntington's disease: Modeling the gait disorder and proposing novel treatments

Journal of Theoretical Biology

Volumn 254, Issue 2, 2008, Pages 361-367

  Banaie, Masood ^a   Sarbaz, Yashar ^b   Gharibzadeh, Shahriar ^b   Towhidkhah, Farzad ^c  

^a SHAHED UNIVERSITY   (Iran)

^b Biomedical Engineering Faculty   (Iran)

^c AMIRKABIR UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

Basal Ganglia (BG); Diazepam; GABA (gamma amino butyric acid); Glutamate

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; DIAZEPAM; NEUROTRANSMITTER;

DISEASE TREATMENT; EXPERIMENTAL STUDY; MODEL VALIDATION; MODELING; NERVOUS SYSTEM DISORDER;

ARTICLE; BASAL GANGLION; CLINICAL FEATURE; GAIT DISORDER; HUNTINGTON CHOREA; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT RESPONSE;

BASAL GANGLIA; COMPUTER SIMULATION; DIAZEPAM; GABA MODULATORS; GAIT; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; MODELS, BIOLOGICAL;

EID: 50149094434     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2008.05.023     Document Type: Article

References (11)

1. Aminoff M.J. Neurology and General Medicine. third ed (2000), Churchill Livingstone, New York
2. Banae, M., Sarbaz, Y., 2005. Modeling the chorea on Huntington disease. In: 12th Iranian Conference on Biomedical Engineering, November 16-18, Tabriz, Iran.
3. Coté L., and Crutcher M.D. The Basal Ganglia. In: Kandel E.R., Schwartz J.H., and Jessell T.M. (Eds). Principles of Neural Science. third ed (1991), Appleton & Lange 647-659 (Chapter 42)
4. Glass M., Dragunow M., and Faull R. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(a) receptor alterations in the human Basal Ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519 10.1016/S0306-4522(00)00008-7
5. Guyton A.C., and Hall J. Textbook of Medical Physiology. 11th ed (2001), Saunders, Boston
6. Haeri M., Sarbaz Y., and Gharibzadeh S. Modeling the Parkinson's tremor and its treatments. J. Theor. Biol. 236 3 (2005) 311-322 10.1016/j.jtbi.2005.03.014
7. Hausdorff J.M., Mitchell S.L., Firtion R., Peng C.K., Cudkowicz M.E., Wei J.Y., et al. Altered fractal dynamics of gait: reduced stride-interval correlations with aging and Huntington's disease. J. Appl. Physiol. 82 1 (1997) 262-269
8. Kandel E.R., Schwartz J.H., and Jessell T.M. Principles of Neural Science. fourth ed (2000), McGraw-Hill, New York
9. Kennedy L., Shelbourne P.F., and Dewar D. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis. Brain Res. 1039 1-2 (2005) 14-21
10. Rothwell J. The Basal Ganglia. In Control of Human Voluntary Movement (1994), Chapman & Hall, London 449-501 (Chapter 11)
11. Sarbaz Y., Banae M., and Gharibzadeh S. A computational model for the Huntington disease. Med. Hypotheses 68 (2007) 1154-1158 10.1016/j.mehy.2006.06.039